Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ('Resverlogix', 'the Company') today announced publication of an article, entitled, 'The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation,' by Dr.

阿尔伯塔省卡尔加里市--（新闻文件公司-2024年1月11日）-Resverlogix公司（TSX:RVX）（“Resverlogix”，“该公司”）今天宣布发表一篇文章，题为“BET抑制剂apabetalone在体外和全身炎症小鼠模型中降低神经内皮促炎激活”。

Sylwia Wasiak and colleagues, in Translational Neuroscience. This publication marks the 40th peer-reviewed scientific journal article published by Resverlogix researchers on apabetalone's potential therapeutic benefits..

Sylwia Wasiak及其同事，《转化神经科学》。本出版物标志着Resverlogix研究人员发表的第40篇同行评审的科学期刊文章，讨论了apabetalone的潜在治疗益处。。

Apabetalone's Publication Record:

Apabetalone的出版记录：

Articles on apabetalone have been published in some of the world's most prestigious scientific journals, including: Nature, Science, Cell, the Journal of the American Medical Association, Cardiovascular Diabetology and the Clinical Journal of the American Society of Nephrologists

关于apabetalone的文章已在世界上一些最著名的科学期刊上发表，包括：《自然》、《科学》、《细胞》、《美国医学会杂志》、《心血管糖尿病学》和《美国肾脏病学会临床杂志》

Resverlogix researchers and our collaborators have published 40 articles on apabetalone in scientific journals, and including work by third-party researchers, there are more than 100 articles on apabetalone in the academic literature

Resverlogix研究人员和我们的合作者在科学期刊上发表了40篇关于apabetalone的文章，包括第三方研究人员的工作，学术文献中有100多篇关于apabetalone的文章

This body of work presents evidence of apabetalone's potential in the treatment of cardiovascular disease, diabetes, post-COVID-19 conditions, chronic kidney disease, and vascular cognitive impairment, as well as rare diseases such as pulmonary arterial hypertension, facioscapulohumeral muscular dystrophy, and Fabry's disease.

这项工作提供了阿帕他隆在治疗心血管疾病，糖尿病，新型冠状病毒肺炎后疾病，慢性肾脏疾病和血管性认知障碍以及罕见疾病（如肺动脉高压，面肩肱型肌营养不良症和法布里病）方面潜力的证据。

The publications also cover a wide spectrum of topics from investigations of apabetalone's mechanism of action at a molecular level, to reports on large-scale clinical trials with thousands of participants

这些出版物还涵盖了广泛的主题，从分子水平上对apabetalone作用机制的研究到数千名参与者的大规模临床试验报告

'We are very proud of our publication record on apabetalone,' said Dr. Ewelina Kulikowski, Chief Scientific Officer at Resverlogix. 'Thanks to the dedicated work of our researchers, we have learned an incredible amount about this drug; how it works, why it's safe, and how it can potentially benefit people suffering from chronic disease.'.

Resverlogix首席科学官EwelinaKulikowski博士说，我们为自己在apabetalone上的出版记录感到骄傲多亏了我们研究人员的辛勤工作，我们对这种药物有了惊人的了解；它是如何工作的，为什么它是安全的，以及它如何可能使患有慢性病的人受益。”。

'The depth and breadth of our knowledge of apabetalone is on full display in the forty scientific articles that we have published to date,' said Donald McCaffrey, President and CEO at Resverlogix. 'We firmly believe that apabetalone will help chronic disease patients, we have published an extraordinary amount of evidence that supports our belief, and we are looking forward to conclusively demonstrating it in our upcoming, Phase 3, cardiovascular disease trial, BETonMACE2.'.

Resverlogix总裁兼首席执行官唐纳德·麦卡弗里（DonaldMcCaffrey）说，我们对apabetalone的了解的深度和广度在迄今为止发表的40篇科学文章中得到了充分展示我们坚信apabetalone将帮助慢性病患者，我们已经发表了大量支持我们信念的证据，我们期待着在即将到来的第三阶段心血管疾病试验BETonMACE2中最终证明这一点。

Highlights from our Latest Publication:

我们最新出版物的亮点：

Inflammation in the small blood vessels of the brain is linked to cognitive impairment and decline

大脑小血管的炎症与认知障碍和衰退有关

Using cultured human brain endothelial cells and monocytes, the authors studied apabetalone's effects on inflammation in these small vessels

利用培养的人脑内皮细胞和单核细胞，作者研究了apabetalone对这些小血管炎症的影响

They found that apabetalone treatment reduced the production of pro-inflammatory molecules and cell-cell interactions

他们发现apabetalone治疗减少了促炎分子的产生和细胞间的相互作用

Their findings were confirmed in a mouse model of brain inflammation, where apabetalone decreased the expression of pro-inflammatory genes

他们的发现在脑部炎症的小鼠模型中得到证实，在该模型中，apabetalone降低了促炎基因的表达

By lessening inflammation in the small blood vessels of the brain, apabetalone may help prevent or treat vascular cognitive impairment

通过减轻大脑小血管的炎症，apabetalone可能有助于预防或治疗血管性认知障碍

Our latest article is published online HERE.

我们的最新文章在这里在线发布。

About Apabetalone

关于Apabethalone

Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes..

Apabetalone（RVX-208）是具有表观遗传作用机制的一流小分子治疗候选药物。它是一种BD2（溴结构域）选择性BET（溴结构域和末端外）抑制剂，通过调节致病基因的表达来预防和治疗疾病。。

Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record across multiple human clinical trials, totaling over 4200 patient-years of safety data..

由于BET蛋白在人体中的广泛作用，apabetalone可以同时靶向多种与疾病相关的生物过程，这代表了治疗慢性疾病的新方法。Apabetalone是同类药物中唯一一种长期服用耐受性良好的药物，在多项人体临床试验中具有既定的安全性记录，总计超过4200患者年的安全性数据。。

Cardiology:

心脏病学：

Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication. This followed the ground-breaking findings from its Phase 3 study, BETonMACE, which showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus..

Apabetalone是第一种获得美国食品和药物管理局针对主要心血管适应症的突破性治疗指定的同类疗法。这是在其第三阶段研究BETonMACE的开创性发现之后进行的，该研究表明，阿帕贝酮可以预防同时患有2型糖尿病的高危心血管疾病患者的主要不良心脏事件。。

About Resverlogix

About Resverlogix

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix成立于2001年，是一家总部位于卡尔加里的晚期生物技术公司，是表观遗传学领域的世界领导者，其目标是为慢性病患者开发一流的疗法。

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.

Resverlogix正在开发一类新的表观遗传疗法，旨在调节致病基因的表达。我们的目标是通过将因心血管疾病等严重疾病而改变的生物功能恢复到更健康的状态来改善患者的生活。

The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.

该公司的临床计划侧重于评估主要的表观遗传学候选药物apabetalone，用于治疗心血管疾病，相关合并症和新型冠状病毒肺炎后疾病。

Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States..

Resverlogix与EVERSANA合作™, 作为全球生命科学行业下一代商业服务的先驱，支持阿帕他隆在加拿大和美国的心血管疾病、新型冠状病毒肺炎后疾病和肺动脉高压方面的快速商业化。。

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Resverlogix普通股在多伦多证券交易所（TSX:RVX）交易。

Follow us: Twitter: @Resverlogix_RVX. LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/.

Follow us: Twitter: @Resverlogix_RVX.LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/.

Forward-Looking Statements:

前瞻性声明：

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words 'believes', 'anticipates', 'plans', 'intends', 'will', 'should', 'expects', 'continue', 'estimate', 'forecasts', and other similar expressions.

本新闻稿可能包含适用的加拿大证券法规定义的某些前瞻性信息，这些信息并非基于历史事实，包括但不限于包含“相信”、“预期”、“计划”、“打算”、“将”、“应该”、“预期”、“继续”、“估计”、“预测”和其他类似表述的声明。

In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, diabetes, chronic kidney disease, vascular cognitive impairment, COVID-19, post COVID-19 conditions, pulmonary arterial hypertension, facioscapulohumeral muscular dystrophy, Fabry's disease, associated comorbidities, and other chronic diseases.

特别是，本新闻稿包括与阿帕他隆在治疗心血管疾病，糖尿病，慢性肾病，血管性认知障碍，新型冠状病毒肺炎，新型冠状病毒肺炎后疾病，肺动脉高压，面肩肱型肌营养不良症，法布里病，相关合并症，和其他慢性疾病。

Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com.

我们的实际结果、事件或发展可能与这些前瞻性声明所表达或暗示的结果、事件或发展存在重大差异。我们不能保证任何事件或期望会发生或实现。就其性质而言，前瞻性陈述受到许多假设和风险因素的影响，包括我们年度信息表和最新MD＆A中讨论的假设和风险因素，这些假设和风险因素通过参考纳入本文，可通过www.SEDAR.com上的SEDAR获得。

The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise..

本新闻稿中包含的前瞻性声明由本警示声明明确限定，并于本公告之日作出。除法律要求外，公司不打算更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。。

For further information please contact:

欲了解更多信息，请联系：

Investor Relations

投资者关系

Email: ir@resverlogix.com

电子邮件：ir@resverlogix.com

Phone: 403-254-9252

电话：403-254-9252

www.resverlogix.com

www.resverlogix.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/193826

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/193826